查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1499968

全球神经调节市场评估：依类型、应用、生物材料、最终用户、地区、机会、预测，2017-2031 年

Neuromodulation Market Assessment, By Type, By Application, By Biomaterial, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 234 Pages | 商品交期: 3-5个工作天内

价格
根据预测，全球神经调节市场规模将从 2023 年的 52.3 亿美元成长到 2031 年的 114.4 亿美元，在 2024-2031 年预测期内复合年增长率为 10.28%。市场的成长是由于帕金森氏症、癫痫、慢性疼痛和偏头痛等各种慢性神经疾病的盛行率不断上升、人们越来越关注开发先进的神经调节技术以及提高人们对神经调节疗法的各种益处的认知而推动的。

各种神经系统疾病盛行率的上升是全球神经调节市场的一个主要趋势。患有慢性疼痛的人数不断增加是推动神经调节疗法和设备需求的主要因素之一。美国疼痛基金会估计，大约有 5,160 万成年人（约占美国人口的 21%）患有慢性疼痛，这增加了对帮助管理和治疗疼痛的神经调节设备的需求。植入式神经调节装置使多裂肌持续收缩，以重建脊椎强度和稳定性并减轻疼痛。

各市场参与者不断努力推出先进且新颖的治疗解决方案，以提高患者的舒适度和便利性，这是推动全球神经调节市场规模的关键因素之一。

本报告研究了全球神经调节市场，并提供了市场概述，包括依类型、应用、生物材料、最终用户、地区和参与市场的公司概况划分的趋势。

目录

第一章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章 2017-2031 年全球神经调节市场展望

  • 市场规模与预测
  • 依类型
  • 依用途
  • 透过生物材料
  • 依最终用户
  • 依地区
  • 各公司的市占率 (%)，2023 年

第五章全球神经调节市场展望（依地区，2017-2031）

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场地图，2023 年

第七章宏观环境与产业结构

  • 供应需求分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

第 9 章监理架构与创新

第十章主要参会企业状况

第11章价格分析

第 12 章案例研究

第 13 章主要进入者展望

  • Medtronic PLC
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Nevro Corporation
  • Synapse Biomedical Inc.
  • Nevro Corporation
  • Neurosigma Inc.
  • Neuronetics Inc.
  • LivaNova PLC
  • Neuropace Inc.

第 14 章策略建议

第十五章查询及免责声明

Product Code: MX11506

Global neuromodulation market is projected to witness a CAGR of 10.28% during the forecast period 2024-2031F, growing from USD 5.23 billion in 2023 to USD 11.44 billion in 2031F. The market's growth is boosted by the increasing prevalence of various chronic neurological conditions, including Parkinson's Disease, epilepsy, chronic pain, migraine, and others, rising emphasis on developing advanced neuromodulation technologies and increasing awareness about various advantages of neuromodulation therapies.

The increasing prevalence of different neurological conditions is a major global neuromodulation market trend. The rising incidence of individuals suffering from chronic pain, among others, is one of the major factors bolstering the demand for neuromodulation therapies and devices. According to the estimates of the US Pain Foundation, approximately 51.6 million adults, almost 21% of the population of the United States, are living with chronic pain, propelling the requirement for neuromodulation devices as they aid in pain management and treatment of the condition. Using implanted restorative neuromodulation devices re-establishes the strength and stability of the spine by providing continuous contractions to the multifidus muscles, resulting in reduced pain.

The growing efforts by various market players towards introducing advanced and novel therapeutic solutions to enhance patient comfort and convenience is one of the major factors boosting the global neuromodulation market size. For instance, in March 2024, Axonics announced that their Axonics R20 rechargeable sacral neuromodulation (SNM) system received CE-mark approval. The R20 provides patients and physicians with expanded magnetic resonance imaging (MRI) labeling and enhanced programming capabilities. R20 underscores Axonics' commitment to innovation and provides a significant breakthrough for rechargeable neuromodulation devices.

Such efforts allow the development of neuromodulation devices that support the treatment of diseases and disorders for which neuromodulation was not previously used. In March 2023, GreyMatters's Prism technology became the first neuromodulation system to receive approval from the Food and Drug Administration (FDA) as an adjunct PTSD treatment. GrayMatters aims to use deidentified data collected throughout Prism treatments to develop patient management tools and treatment predictors.

Research and Development Activities Support Global Neuromodulation Market Growth

The growing efforts by various organizations and companies towards research and development activities are expected to support the market expansion in the coming years. Such efforts bolster the development of advanced technologies and products, which are then approved for use by suitable regulatory bodies. For instance, in January 2024, Neurolief's Relivion received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) as a migraine therapy in Japan. The device uses multi-channel and non-invasive brain neuromodulation technology and stimulates both trigeminal and occipital nerve branches, neural pathways that are responsible for migraine. RelivionMG, which is used for treating acute migraines, received approval from the U.S. FDA.

Research and development activities enhance patient convenience and aid in developing high-quality products to ensure better patient outcomes. They allow the translation of ideas, aiding healthcare professionals in addressing the different requirements of their patients and making therapies and products accessible, affordable, and acceptable. Due to the growing burden of different neurological conditions, including migraine and Parkinson's, the investments in research and development activities are increasing, thus bolstering product innovation and positively influencing the expansion of the market.

Increasing Prevalence of Neurological Conditions Boosts Global Neuromodulation Market Demand

According to the estimates of the World Health Organization (WHO), more than 50 million people across the globe are living with epilepsy, which is one of the most common neurological diseases. The approved neuromodulation therapies for treating adults with drug-resistant focal epilepsy include responsive neurostimulation, deep brain stimulation of the anterior nucleus of the thalamus, and vagus nerve stimulation.

The rising number of different neurological conditions such as migraine, epilepsy, and chronic pain, coupled with increasing awareness and rate of diagnosis, is propelling the requirement for neuromodulation devices across the globe. This is because treating several disorders relies upon creating focal points or biological and chronic noncurative pharmacologic treatments. The broad therapeutic potential of neuromodulation and ongoing improvements in biotechnology are providing lucrative growth opportunities to the market. Moreover, neuromodulation devices are capable of stimulating responses in conditions where previously they weren't available, including the cochlear implant, which is used to restore hearing for deaf patients. Thus, as the prevalence of different neurological conditions increases, the demand for neuromodulation devices is expected to rise, supporting the expansion of the market.

North America to Account for Significant Global Neuromodulation Market Share

The strong presence of several leading market players, rising emphasis on developing novel therapeutics solutions, and growing requirement for neuromodulation devices due to the increasing prevalence of neurological disorders are major factors augmenting the market growth in North America. The rising investments by leading market players in research and development activities provide lucrative growth opportunities for the market as these activities support the innovation of products with advanced technologies.

As per the estimates of the American Migraine Foundation, approximately 39 million Americans are living with migraine. Due to the rising prevalence of such conditions, the requirement for different treatment solutions is increasing, including neuromodulation devices. The high rate of adoption of advanced and novel technologies in the region, coupled with increased investments in the biopharmaceutical and pharmaceutical sectors, is further propelling the growth of the market.

Parkinson's Disease Accounts for Significant Global Neuromodulation Market Share

The increasing prevalence of Parkinson's disease in various regions across the globe is providing lucrative growth opportunities to the market. According to the estimates of the Parkinson's Foundation, approximately 90,000 individuals are diagnosed with Parkinson's disease every year in the United States. Parkinson's disease is characterized by various motor symptoms such as postural instability, rigidity, tremors, and bradykinesia. The physiological dysfunction of the condition involves basal ganglia pathways that contribute towards non-motor and motor symptoms, the pathways can be influenced by neural network modulations with the help of magnetic or electrical fields. Deep brain stimulation is often used for treating the condition by applying small pulses of electrical currents at various locations in the brain using implanted electrodes. The stimulations then aid in restoring the circuit balance that had been disrupted by the condition. They alleviate tremors and reduce dyskinesias and stiffness and are highly effective against on and off fluctuations. Thus, bolstering the demand for neuromodulation devices. Additionally, rising efforts towards the development of noninvasive neuromodulation technologies as potential treatments for Parkinson's disease is expected to provide lucrative growth opportunities to the market in the coming years.

Future Market Scenario (2024 - 2031F)

According to the global neuromodulation market analysis, the market is expected to grow significantly over the forecast period. The growth will be supported by the increase in the number of cases of various neurological diseases such as migraine, rising collaborations between the key players of the market, and growing investments towards research activities by various research institutions across the globe. For instance, the University of Calgary is conducting an interventional study to assess the working of a novel neuromodulation device for acute migraine attacks in children and adolescents. The randomized clinical trial aims to determine the acceptability and feasibility of implementing phase III RCT for treating adolescents and children suffering from acute migraine attacks. The study aims to gather preliminary safety and efficacy data on the utilization of REN and is expected to conclude in August 2024.

Over the coming years, the advancements in the understanding of mechanism of action of stimulation and neuroanatomical networks along with advancements in miniaturization and material sciences will bolster the utilization of neuromodulation devices. The future modulation methods are expected to aim for reduced invasiveness and high specificity.

Key Players Landscape and Outlook

The growth of the market is supported by successful mergers and collaborations and acquisitions that allow companies to expand their customer base and enhance their product portfolio. In September 2023, Boston Scientific Corporation announced that they had successfully acquired Relievant Medsystems, Inc., the medical technology company known for commercializing and developing the Intracept Intraosseous Nerve Ablation System for treating vertebrogenic pain. Relievant Medsystems is expected to witness year over year growth that exceeds 50% in 2024. The acquisition intends to support the expansion of the neuromodulation portfolio of Boston Scientific, allowing them to provide more treatment solutions for patients living with chronic back pain.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Neuromodulation Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. External Neuromodulation
      • 4.2.1.1. Transcranial Magnetic Stimulator
      • 4.2.1.2. Respiratory Electrical Stimulator
      • 4.2.1.3. Transcutaneous Electrical Nerve Stimulator
    • 4.2.2. Internal Neuromodulation
      • 4.2.2.1. Spinal Cord Stimulator
      • 4.2.2.2. Vagus Nerve Stimulator
      • 4.2.2.3. Gastric Electrical Stimulator
      • 4.2.2.4. Deep Brain Stimulator
      • 4.2.2.5. Sacral Nerve Stimulator
  • 4.3. By Application
    • 4.3.1. Parkinson's Disease
    • 4.3.2. Failed Back Syndrome
    • 4.3.3. Tremor
    • 4.3.4. Depression
    • 4.3.5. Urinary and Fecal Incontinence
    • 4.3.6. Chronic Pain Management
    • 4.3.7. Dystonia
    • 4.3.8. Migraine
    • 4.3.9. Epilepsy
    • 4.3.10. Others
  • 4.4. By Biomaterial
    • 4.4.1. Polymeric Biomaterials
    • 4.4.2. Metallic Biomaterials
    • 4.4.3. Ceramic Biomaterials
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Specialty Clinics
    • 4.5.3. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. South America
    • 4.6.3. Europe
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Neuromodulation Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. External Neuromodulation
        • 5.1.2.1.1. Transcranial Magnetic Stimulator
        • 5.1.2.1.2. Respiratory Electrical Stimulator
        • 5.1.2.1.3. Transcutaneous Electrical Nerve Stimulator
      • 5.1.2.2. Internal Neuromodulation
        • 5.1.2.2.1. Spinal Cord Stimulator
        • 5.1.2.2.2. Vagus Nerve Stimulator
        • 5.1.2.2.3. Gastric Electrical Stimulator
        • 5.1.2.2.4. Deep Brain Stimulator
        • 5.1.2.2.5. Sacral Nerve Stimulator
    • 5.1.3. By Application
      • 5.1.3.1. Parkinson's Disease
      • 5.1.3.2. Failed Back Syndrome
      • 5.1.3.3. Tremor
      • 5.1.3.4. Depression
      • 5.1.3.5. Urinary and Fecal Incontinence
      • 5.1.3.6. Chronic Pain Management
      • 5.1.3.7. Dystonia
      • 5.1.3.8. Migraine
      • 5.1.3.9. Epilepsy
      • 5.1.3.10. Others
    • 5.1.4. By Biomaterial
      • 5.1.4.1. Polymeric Biomaterials
      • 5.1.4.2. Metallic Biomaterials
      • 5.1.4.3. Ceramic Biomaterials
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Specialty Clinics
      • 5.1.5.3. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
        • 5.1.6.1.1. By Value
        • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Type
        • 5.1.6.2.1. External Neuromodulation
          • 5.1.6.2.1.1. Transcranial Magnetic Stimulator
          • 5.1.6.2.1.2. Respiratory Electrical Stimulator
          • 5.1.6.2.1.3. Transcutaneous Electrical Nerve Stimulator
        • 5.1.6.2.2. Internal Neuromodulation
          • 5.1.6.2.2.1. Spinal Cord Stimulator
          • 5.1.6.2.2.2. Vagus Nerve Stimulator
          • 5.1.6.2.2.3. Gastric Electrical Stimulator
          • 5.1.6.2.2.4. Deep Brain Stimulator
          • 5.1.6.2.2.5. Sacral Nerve Stimulator
      • 5.1.6.3. By Application
        • 5.1.6.3.1. Parkinson's Disease
        • 5.1.6.3.2. Failed Back Syndrome
        • 5.1.6.3.3. Tremor
        • 5.1.6.3.4. Depression
        • 5.1.6.3.5. Urinary and Fecal Incontinence
        • 5.1.6.3.6. Chronic Pain Management
        • 5.1.6.3.7. Dystonia
        • 5.1.6.3.8. Migraine
        • 5.1.6.3.9. Epilepsy
        • 5.1.6.3.10. Others
      • 5.1.6.4. By Biomaterial
        • 5.1.6.4.1. Polymeric Biomaterials
        • 5.1.6.4.2. Metallic Biomaterials
        • 5.1.6.4.3. Ceramic Biomaterials
      • 5.1.6.5. By End-user
        • 5.1.6.5.1. Hospitals
        • 5.1.6.5.2. Specialty Clinics
        • 5.1.6.5.3. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Application
  • 6.3. By Biomaterial
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Medtronic PLC
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Boston Scientific Corporation
  • 13.3. Abbott Laboratories
  • 13.4. Nevro Corporation
  • 13.5. Synapse Biomedical Inc.
  • 13.6. Nevro Corporation
  • 13.7. Neurosigma Inc.
  • 13.8. Neuronetics Inc.
  • 13.9. LivaNova PLC
  • 13.10. Neuropace Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 6. Global Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Neuromodulation Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 11. North America Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 12. North America Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 13. North America Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Neuromodulation Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 18. United States Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 19. United States Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 20. United States Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 24. Canada Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 25. Canada Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 26. Canada Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 30. Mexico Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 31. Mexico Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 32. Mexico Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 36. Europe Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 37. Europe Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 38. Europe Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Neuromodulation Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 43. Germany Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 44. Germany Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 45. Germany Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 49. France Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 50. France Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 51. France Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 55. Italy Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 56. Italy Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 57. Italy Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 61. United Kingdom Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 62. United Kingdom Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 63. United Kingdom Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 67. Russia Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 68. Russia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 69. Russia Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 73. Netherlands Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 74. Netherlands Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 75. Netherlands Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 79. Spain Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 80. Spain Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 81. Spain Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 85. Turkey Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 86. Turkey Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 87. Turkey Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 91. Poland Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 92. Poland Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 93. Poland Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 97. South America Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 98. South America Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 99. South America Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Neuromodulation Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 104. Brazil Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 105. Brazil Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 106. Brazil Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 110. Argentina Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 111. Argentina Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 112. Argentina Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 116. Asia-Pacific Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 117. Asia-Pacific Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 118. Asia-Pacific Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Neuromodulation Market Share (%), By Country, 2017-2031F
  • Figure 120. India Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 123. India Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 124. India Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 125. India Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 129. China Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 130. China Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 131. China Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 135. Japan Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 136. Japan Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 137. Japan Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 141. Australia Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 142. Australia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 143. Australia Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 147. Vietnam Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 148. Vietnam Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 149. Vietnam Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 153. South Korea Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 154. South Korea Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 155. South Korea Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 159. Indonesia Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 160. Indonesia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 161. Indonesia Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 165. Philippines Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 166. Philippines Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 167. Philippines Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 171. Middle East & Africa Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 172. Middle East & Africa Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 173. Middle East & Africa Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Neuromodulation Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 178. Saudi Arabia Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 179. Saudi Arabia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 180. Saudi Arabia Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 184. UAE Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 185. UAE Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 186. UAE Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Neuromodulation Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Neuromodulation Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Neuromodulation Market Share (%), By Type, 2017-2031F
  • Figure 190. South Africa Neuromodulation Market Share (%), By Application, 2017-2031F
  • Figure 191. South Africa Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
  • Figure 192. South Africa Neuromodulation Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Biomaterial Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023